Urogen Pharma (URGN) Price Target Increased to $37.00 by Analysts at Jefferies Group LLC
Urogen Pharma (NASDAQ:URGN) had its target price lifted by Jefferies Group LLC from $27.00 to $37.00 in a research note published on Monday morning. Jefferies Group LLC currently has a buy rating on the stock.
A number of other research analysts have also recently weighed in on URGN. Zacks Investment Research cut shares of Urogen Pharma from a hold rating to a sell rating in a research note on Thursday, September 14th. Oppenheimer Holdings, Inc. set a $32.00 target price on shares of Urogen Pharma and gave the company a buy rating in a research note on Monday, August 14th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $28.50.
COPYRIGHT VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/10/13/urogen-pharma-urgn-price-target-increased-to-37-00-by-analysts-at-jefferies-group-llc.html.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Alps Advisors Inc. purchased a new position in Urogen Pharma in the second quarter valued at about $195,000. LLBH Private Wealth Management LLC purchased a new position in Urogen Pharma in the second quarter valued at about $695,000. Spark Investment Management LLC purchased a new position in Urogen Pharma in the second quarter valued at about $856,000. Menora Mivtachim Holdings LTD. purchased a new position in Urogen Pharma in the second quarter valued at about $2,331,000. Finally, Wildcat Capital Management LLC purchased a new position in Urogen Pharma in the second quarter valued at about $2,439,000. Hedge funds and other institutional investors own 36.06% of the company’s stock.
About Urogen Pharma
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
Receive News & Stock Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related stocks with our FREE daily email newsletter.